Register Login

KODIAK SCIENCES INC. (KOD)

(10% Negative) KODIAK SCIENCES INC. (KOD) Announces Delay in opportunities Trials for Kodiak Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot May 7, 2026, 8:02 p.m.

    📋 KODIAK SCIENCES INC. (KOD) - Clinical Trial Update

    Filing Date: 2026-05-07

    Accepted: 2026-05-07 16:00:20

    Event Type: Clinical Trial Update

    Event Details:

    KODIAK SCIENCES INC. (KOD) Announces Clinical Trial Update KODIAK SCIENCES INC. (KOD) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: opportunities, readout
    • Diseases/Conditions: Kodiak, PEAK Phase 3 in MESI
    • Clinical Stage: Phase 3 study, Phase 3
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: MESI
      • - Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent Management Commentary: '"Kodiak has entered 2026 with continued momentum and increasing clarity as we advance toward key clinical readouts and our first planned regulatory submission," said Victor Perlroth'
        • expected in 4Q 2026
        • expected in 2Q 2027
        • targeting disease biology beyond VEGF for differentiated efficacy. KSI-501 is designed to provide high immediacy/efficacy, driven by the enhanced formulation, and high durability, driven by the ABC platform and our science of durability. In preclinical models, KSI-501 was shown to be a potent inhibitor of VEGF and IL-6 and, further, was shown to normalize the blood retinal barrier, opening up the possibility that KSI-501 may be a disease-modifying therapy for retinal vascular diseases. Furthermore, higher intraocular levels of IL-6 correlated with poorer BCVA outcomes over time in wet AMD patients treated with anti-VEGF monotherapy, which suggests that IL-6 inhibition in combination with anti-VEGF therapy could lead to improved outcomes. Kodiak has advanced KSI-501 into the Phase 3 study DAYBREAK to evaluate its efficacy and safety in wet AMD. DAYBREAK has completed enrollment. DAYBREAK uses KSI-501's enhanced 50 mg/mL formulation containing both conjugated and unconjugated antibody that is intended to balance immediacy and durability. Topline data for the one-year primary endpoint in DAYBREAK are expected in 3Q 2026

    🔬 Clinical Development Pipeline (KODIAK SCIENCES INC.):

    Product Type Development Stage Therapeutic Area Source
    Aflibercept Other Phase PHASE3 Macular Edema ClinicalTrials.gov
    KSI-101 Other Phase PHASE3 Macular Edema Secondary to Inflammation ClinicalTrials.gov
    Sham Comparator Other Phase PHASE3 Macular Edema Secondary to Inflammation ClinicalTrials.gov
    KSI-301 Other Phase PHASE1 Wet Age-related Macular Degeneration ClinicalTrials.gov
    Sham Procedure Procedure Phase PHASE3 Macular Edema ClinicalTrials.gov
    Sham injection Other Phase PHASE3 Non-proliferative Diabetic Retinopathy ClinicalTrials.gov
    Tarcocimab Other Phase PHASE3 Diabetic Retinopathy ClinicalTrials.gov
    Tabirafusp tedromer Other Phase PHASE3 Wet Age-related Macular Degeneration ClinicalTrials.gov
    Tarcocimab tedromer Other Phase PHASE3 Wet Age-related Macular Degeneration ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: KODIAK SCIENCES INC.
    • Ticker Symbol: KOD

Search

News categories